NewsBytes
    Hindi Tamil Telugu
    More
    In the news
    Narendra Modi
    Amit Shah
    Box Office Collection
    Bharatiya Janata Party (BJP)
    OTT releases
    Hindi Tamil Telugu
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / India News / Hetero seeks Emergency Use Authorization for Molnupiravir in India
    Hetero seeks Emergency Use Authorization for Molnupiravir in India
    India

    Hetero seeks Emergency Use Authorization for Molnupiravir in India

    Written by Astha Oriel
    (PTI desk)
    July 09, 2021 | 09:01 pm 2 min read
    Hetero seeks Emergency Use Authorization for Molnupiravir in India
    Credits
    Citing the Phase III trial data of Molnupiravir, Hetero says it has resulted in early recovery of mild COVID-19 patients

    The use of Molnupiravir, an experimental oral drug having antiviral properties, has resulted in early recovery of COVID-19 patients with mild symptoms when compared to standard treatment during Phase III clinical trials, Hetero said on Friday citing interim data. The Hyderabad-based drugmaker also said it has approached the Drug Controller General of India (DCGI) seeking Emergency Use Authorisation (EUA) for Molnupiravir in India.

    It has conducted Phase III trial on mild COVID-19 patients

    Hetero had commenced a Phase III, comparative, randomized, multicenter clinical trial on mild COVID-19 patients. These clinical trials were aimed at evaluating the efficacy and safety of Molnupiravir plus standard of care (test arm) versus standard of care alone (control arm) in mild COVID-19 patients with a positive SARS-CoV-2 RT-PCR test for COVID-19 and randomized within five days of onset of symptoms.

    Here is how the trial was conducted

    The experiment was conducted in two methods. The Times of India reported that patients in the trial were randomized to receive either the Molnupiravur capsules 800mg (4*200 mg) every 12 hours twice daily for five days, along with the standard case as per the Indian Council of Medical Research (ICMR), guidelines or to receive standard of care alone in the control arm.

    Hetero had an agreement with MSD for Molnupiravir's manufacturing, supply

    There were fewer hospital admissions in the Molnupiravir group compared to the standard of care alone over 14 days of observation, the interim results said. Notably, in April this year, Hetero had entered into a non-exclusive licensing agreement with MSD (trade name for the US-based Merck & Co., Inc.) to manufacture and supply Molnupiravir in India and over 100 low and middle-income countries (LMICs).

    What Hetero said regarding the Phase III trial

    "Phase III trial demonstrates statistically significant fewer hospital admissions, faster time to clinical improvement and early negative SARS-CoV-2 RT-PCR with Molnupiravir treatment in mild COVID-19 patients compared to standard of care alone," Hetero said.

    Hetero is conducting a separate study on moderate COVID-19 patients

    "There was no mortality in either (Phase III) group and all adverse events were non-serious, mild in severity, and none led to drug discontinuation," Hetero said. The most common adverse events reported were nausea, diarrhea, and headache which were resolved completely, according to Hetero, which is also undertaking a separate Molnupiravir study on moderate COVID-19 patients approved by Central Drugs Standard Control Organization (CDSCO).

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Related News
    Indian Council of Medical Research (ICMR)
    Drugs Controller General of India
    Coronavirus
    COVID-19

    Indian Council of Medical Research (ICMR)

    COVID-19: Delta Plus variant has spread to 12 Indian states India
    'Medicine from the Sky': Telangana testing drone delivery of vaccines India
    India will soon test mixing different COVID-19 vaccines India
    Secondary infections, including fungal, causing COVID-19 death spike: ICMR study Coronavirus

    Drugs Controller General of India

    DRDO nod for Mankind Pharma to manufacture COVID-19 drug 2-DG Defence Research and Development Organisation (DRDO)
    Expert panel says no to Covovax's children trials in India Central Drugs Standard Control Organization (CDSCO)
    Zydus applies for approval of its 3-dose, needle-free COVID-19 vaccine Zydus Cadila
    Bharat Biotech submits COVAXIN phase-3 trial data, review meet today COVID-19

    Coronavirus

    PM Modi chairs top-level meet on coronavirus, oxygen availability Narendra Modi
    Uttar Pradesh reports 2 cases of Kappa COVID-19 variant India
    Zydus vaccine for 12-18-year-olds from September, says expert panel chief Zydus Cadila
    No room for carelessness, complacency: PM Modi on COVID-19 situation Narendra Modi

    COVID-19

    Sri Lanka vs India series to be rescheduled: Details here Cricket: News, Stats and more!
    After batting coach, SL team's data analyst tests COVID-19 positive Cricket: News, Stats and more!
    New drug target to treat coronavirus, fight future pandemic found Research
    Indraprastha Apollo records six cytomegalovirus infection cases in a month Delhi
    Next News Article

    Love India News?

    Subscribe to stay updated.

    India Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023